Health X Platform Limited (formerly Sastasundar Ventures Limited) has received board approval for executing a tripartite agreement with its material subsidiary Sastasundar Healthbuddy Limited (SHBL) and Envision India Fund. The board of directors approved the agreement execution under Regulation 30A of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Agreement Framework and Parties

The tripartite agreement involves Health X Platform Limited, SHBL, and Envision India Fund, a qualified institutional buyer registered in Mauritius with registration number GB20025232. The agreement follows the share purchase agreement dated February 25, 2026, where Envision acquired Mitsubishi Corporation's entire shareholding in SHBL comprising 10.14 lakh equity shares valued at Rs. 50.00 crore at Rs. 493.21 per share.

Merger and Share Swap Provisions

The tripartite agreement contemplates a scheme of arrangement between Health X Platform and SHBL, whereby SHBL shall be merged with Health X Platform subject to compliance with applicable laws. The merger structure ensures Envision's economic interest in Health X Platform post-merger remains equivalent to its pre-merger stake in SHBL.

If the scheme of arrangement resulting in merger cannot be consummated, Health X Platform will undertake a share swap arrangement to provide Envision equivalent shares in lieu of SHBL holdings. The company previously disclosed in-principle approval for the merger scheme on February 26, 2026.

Post-Transaction Shareholding Structure

Following the completion of the transaction, SHBL's shareholding structure comprises Health X Platform Limited holding 17,100,160 equity shares, Rohto Pharmaceuticals Co., Ltd. with 3,562,064 equity shares, and Envision India Fund with 10,13,766 equity shares, totaling 21,675,990 equity shares.

Governance Rights and Board Representation

The tripartite agreement grants Envision India Fund the right to nominate one director on Health X Platform's board in case of material breach or non-consummation of the merger. This provision ensures Envision maintains governance participation aligned with its investment stake and strategic interests in the healthcare platform.

Regulatory Compliance and Disclosure

Company Secretary and Compliance Officer Pratap Singh executed the regulatory disclosure under SEBI guidelines, maintaining transparency with stock exchanges. The transaction falls within related party transaction scope as SHBL is a material subsidiary of Health X Platform, with the company being SHBL's promoter.

Sastasundar ventures has disclosed multiple share acquisitions by its promoter under SEBI insider trading regulations. The company has informed BSE and NSE about these transactions through formal disclosures, demonstrating continued promoter confidence in the company.

Recent Promoter Share Acquisitions

Promoter Banwari Lal Mittal has made two separate acquisitions of equity shares through market purchases. The first transaction was executed on 11.02.2026, followed by another acquisition on 18.02.2026, both intimated to the company on their respective transaction dates.

Transaction Summary

The market purchases involved a total of 13,000 equity shares across two transactions with a combined transaction value of Rs. 38,68,525.02, inclusive of taxes. These acquisitions represent a strategic increase in the promoter's stake in the company.

Progressive Shareholding Changes

The cumulative effect of both transactions shows a steady increase in promoter shareholding, reflecting continued confidence in the company's prospects.

Regulatory Compliance

Both disclosures were made pursuant to Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. Company Secretary and Compliance Officer Pratap Singh submitted the required Form C to both BSE (Stock Code: 533259) and NSE (Symbol: SASTASUNDR) for each transaction.

The company confirmed that no derivative trading was involved in either transaction, with all derivative-related fields marked as "N.A." in the regulatory filings. These acquisitions strengthen the promoter's position in Sastasundar Ventures Limited while maintaining full regulatory compliance throughout both transactions.